We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Home

Welcome to NLS Pharmaceutics

We are seeking to design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are seeking to create new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Room

Interview with Alex Zwyer, CEO of NLS Pharmaceutics Ltd. (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section

Latest News

Mar 2, 2020
NLS Pharmaceutics Ltd. (NLS) Files Registration Statement for a Proposed Initial Public Offering
Jan 13, 2020
Adare Pharmaceuticals and NLS Pharmaceutics collaborate to develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy
Sep 30, 2019
NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio.
Aug 13, 2019
NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity

Partnerships

Contact us

NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.

NLS PHARMACEUTICS GROUP
Alter Postplatz 2
CH-6370 Stans NW
Switzerland

T: +41 41 618 80 00
F: +41 41 618 80 09
askus@nls-pharma.com

About
Our DNA
Mission & Values

Science
R&D Strategy
R&D Focus
Pipeline
Mazindol

Partnering
Academic Collaborations
Industry Partnerships

News
Press Releases
Press Room
Awards

Contact
Contact

Legal
Privacy Policy
Terms & Conditions
Cookies Disclaimer/